The Immune Development in Pediatric Transplantation (IMPACT) study was conducted to evaluate relationships among alloimmunity, protective immunity, immune development, physical parameters, and clinical outcome in children undergoing kidney transplantation. We prospectively evaluated biopsyproven acute rejection (BPAR), de novo donorspecific antibody (dnDSA) formation, viremia, viral infection, T cell immunophenotyping, and body mass index (BMI)/weight Z scores in the first year posttransplantation in 106 pediatric kidney transplant recipients. Outcomes were excellent with no deaths and 98% graft survival. Rejection and dnDSAs occurred in 24% and 22%, respectively. Pretransplant cytomegalovirus (CMV) and Epstein-Barr virus (EBV) serologies and subsequent viremia were unrelated to BPAR or dnDSA. Viremia occurred in 73% of children (EBV, 34%; CMV, 23%; BMK viremia, 23%; and JC virus, 21%). Memory lymphocyte phenotype at baseline was not predictive of alloimmune complications. Patients who developed viral infection had lower weight (À2.1) (p = 0.028) and BMI (À1.2) (p = 0.048) Z scores at transplantation. The weight difference persisted to 12 months compared with patients without infection (p = 0.038). These data indicate that there is a high prevalence of viral disease after pediatric kidney transplantation, and underweight status at transplantation appears to be a risk factor for subsequent viral infection. The occurrence of viremia/viral infection is not associated with alloimmune events.
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Introduction
Kidney transplantation is the optimal treatment for children with end-stage renal disease (ESRD) (1) (2) (3) . Nonetheless, significant morbidities still exist, primarily related to dependence on nonspecific immunosuppression. Immunosuppressive agents impair protective immunity against infection while simultaneously yielding only partial protection from rejection (4) .
In addition to the obvious changes in physical development, childhood and adolescence are times of both dynamic immunological evolution and exposure/response to viral pathogens. During this time, the adaptive cellular immune system of childhood changes from an exclusively na€ ıve to a "memory" repertoire (5) (6) (7) . At the same time, children encounter innumerable viruses, developing immunity against some and establishing latency with others (e.g. herpesviruses) (8, 9) . The impact of these changes in viral status and immune cell maturation on transplant outcomes has not been prospectively examined.
In solid organ transplantation, viral infections have been linked to adverse clinical alloimmune outcomes. A number of mechanisms have been proposed whereby viral infections might mediate allograft dysfunction and/or rejection (10) . These include direct virus-mediated inflammation and graft injury (11) , acute rejection mediated by T cells with cross-reactivity between donor alloantigens and pathogen-associated antigens (termed heterologous immunity) (12) , bystander activation of resting T cells driven by proinflammatory signals initiated in response to a posttransplantation viral infection (13) , and rejection related to the heightened alloimmune reactivity when immunosuppression is decreased in the face of viral infection (14) (15) (16) . In pediatric transplantation, children and adolescents exist in a theoretically precarious balance, particularly in the first posttransplantation year, when both immunosuppressive medication doses and the danger of rejection are highest. Insufficient immunosuppression risks alloimmune responses to the graft, including rejection and alloantibody formation. Excessive immunosuppression increases the incidence of opportunistic infection, often viral in nature. Few prospective data exist to establish relationships between ongoing immune maturation, infection and adverse alloimmune events in children after kidney transplantation. It is also unclear which factors independently influence the incidence of viral infection and whether these are the same factors that predict rejection or generation of donor-specific alloantibodies (DSAs).
The Immune Development in Pediatric Transplantation (IMPACT) study was a prospective, multicenter, observational study of pediatric kidney transplant recipients designed to examine the natural history of pediatric kidney transplantation in the first posttransplantation year and to explicitly evaluate relationships among alloimmunity, protective immunity, viremia, immune development, physical development, and clinical outcome in children undergoing kidney transplantation. The study focused on pretransplantation herpesvirus experience (using donor and recipient serostatus), posttransplantation viral acquisition (using comprehensive, longitudinal viral polymerase chain reaction [PCR]-based viral monitoring), and the immunophenotyping of T cell memory. We examined the relationship of these factors to clinical outcomes including symptomatic viral infection, biopsyproven acute allograft rejection (BPAR), and de novo DSA (dnDSA) formation. We surveyed a broader range of viruses than have previously been examined, and combined this with a validated set of surface antigen markers for T cell memory. In this report, we address the following questions: Does viral status (prior viral exposure, viremia or clinical viral infection) influence alloimmune outcomes? Can clinical risk be anticipated based on pretransplantation memory T cell acquisition or cytomegalovirus (CMV)/Epstein-Barr virus (EBV) seropositivity (17) ? And do physical parameters before or during transplantation influence viral or alloimmune outcomes?
Materials and Methods

Patients
This was a multicenter prospective observational cohort study (ClinicalTrials.gov NCT00951353) in pediatric kidney transplant recipients conducted at three institutions. Eligible patients were between 1 and 20 years of age at enrollment and undergoing their first kidney transplant. Recipients of multiple organ transplants were excluded. Informed consent was obtained from the patient's parent/legal guardian or the subject (≥18 years old). The institutional review boards of each institution approved the study protocol.
We serially examined posttransplantation alloimmune events (BPAR and DSA), T cell immunophenotyping, and viremia using PCR testing for nine different viruses. We then examined the relationship of these parameters to pretransplantation viral exposure and to posttransplantation indices of growth and nutrition. To assess the patients' viral antigen exposure, subjects were categorized based on preenrollment CMV and EBV serology testing. These viruses were chosen as surrogates for broader immune exposure based on the ubiquitous nature of their testing pretransplantation. Enrolled children were placed in one of three groups: viral seropositive (seropositive for both CMV and EBV), viral seronegative (seronegative for both CMV and EBV), or split serology (positive for either CMV or EBV but not both).
The trial was powered on a preliminary hypothesis that the pretransplantation seropositivity might be associated with an increase in the risk of BPAR (17) . The target accrual was 100 patients, to be followed for 1 year. The study had 86% power to detect the difference between a rejection rate of 35% in CMV/EBV seropositive patients and versus 5% in viral na€ ıve (i.e. seronegative) patients.
Trial conduct
Transplantations and subsequent immunosuppressive management were performed according to the clinical standard at each site ( Table 1) . The majority of patients (n = 103; 97%) received anti-CMV prophylaxis: intravenous ganciclovir transitioned to oral valganciclovir. Valganciclovir was administered for an average of 93 days (range 1-358 days, median 79 days). Study visits occurred at months 1, 3, 6, 9, and 12 after transplantation (see Data S1), at which time children were assessed for alloimmune failure (BPAR and/or DSAs) and protective immune failure (all-cause infection, viral infection, and/ or viremia). Estimated glomerular filtration rates (eGFRs) were determined by using the updated Schwartz formula (18) .
Diagnosis of BPAR
Surveillance biopsies were performed at 6 months and 1 year. Clinically indicated biopsies were performed at the discretion of the treating physician. Treatment was based on the local biopsy interpretation. A designated central pathologist (R.S.), blinded to the clinical circumstance, also read slides retrospectively. A study diagram is shown in Figure 1 .
Assessment of alloantibodies
HLA typing for HLA-A, -B, -DRB1, -DRB3/4/5, and -DQB1 loci was performed by using molecular methods. Additional typing for HLA-C, -DQA1, -DPA1, and -DPB1 and MHC class I polypeptide-related sequence A (MICA) was performed as needed to assign DSA. HLA and MICA antibodies were considered positive when the normalized mean fluorescence intensity value was >1000, with the exception of antibodies to HLA-Cw antigens (positive >2000) (19) (see Data S1).
Infection assessment
Patients were assessed for bacterial, viral, fungal, and parasitic infection at each visit and as clinically indicated using the local laboratories.
Infections were considered clinically significant if they were culture or PCR positive and treated. Viremia was also surveyed centrally at each study visit using a protocol PCR-based assay for BK viremia (BKV), CMV, EBV, adenovirus, JC virus, and human herpesvirus 6 (HHV6), HHV7, and HHV8 (see Data S1).
Flow cytometry
At baseline and at months 1, 2, 6, 9, and 12, peripheral blood was drawn into Cyto-chex tubes (Streck Laboratories, Omaha, NE). T cells were segregated based on CD3 expression, divided into CD4-and CD8-expressing subsets, then further segregated into na€ ıve (CD45RA 
Clinical endpoints
Alloimmune failure (AF) was defined as the presence of either BPAR or dnDSAs. For the purposes of maximal sensitivity analysis, BPAR assessed centrally included all Banff grades plus those biopsies read as "borderline." Viremia was identified by central or local laboratory PCR when there were ≥100 copies/mL. From the total of 106 patients, we subclassified patients into three distinct, "phenotypically pure" groups. These were defined as (1) patients who during their follow-up had no BPAR, viremia, or viral infection; (2) patients who had either viral infection by local assessment or viremia with >10 000 copies with no BPAR; or (3) patients who had only BPAR confirmed by the central pathologist.
Statistical analysis
Continuous variables were summarized with the means and standard deviations and categorical variables with counts and percentages. Patient characteristics were compared by using v 2 , Fisher's exact, or CochranMantel-Haenszel tests for categorical variables and t-tests for continuous variables. Univariate and multivariable logistic regression models were used to describe relationships between clinical outcomes and patient characteristics. Selected baseline characteristics and on-study covariates meeting the p = 0.1 criterion stayed in the model and were used to construct the final multivariable logistic regression model presented. F-tests from a generalized linear model were used for the height, weight, and BMI Z score analyses. A generalized multivariate mixed model was used to analyze the relationship between the repeated flow cytometric measures of CD4 and CD8 and clinical outcomes. Log10 transformations were applied as necessary to satisfy normal distribution assumptions. All statistical analyses were performed by using SAS Version 9.3 (SAS Institute, Inc., Cary, NC).
Results
Demographics
Between July 2009 through October 2011, 125 patients were enrolled and 106 proceeded to transplantation. Ninety-nine (93%) patients completed 1 year of followup. Of the 106 patients, four were not evaluable for alloimmune failure and seven were not evaluable for BPAR ( Figure 1 ). Eighty (75%) of the 106 received deceased donor transplants. The mean age of the 106 transplanted patients was 11.9 AE 6.20 years; 66% were male (Table 1) . Compared with the 2014 North American Pediatric Renal Transplant Cooperative Study (NAPRTCS) database, African Americans were underrepresented (13% vs. approximately 18%), while Hispanics were overrepresented (44% vs. approximately 18%) (https:// web.emmes.com/study/ped/annlrept/annualrept2014.pdf).
Immunosuppression
All patients received immediate induction therapy. Rabbit polyclonal anti-thymocyte globulin (Thymoglobulin; Genzyme, Cambridge, MA) was used in 26%. Seventy-seven percent received an anti-CD25 monoclonal antibody; 34% received the chimeric antibody basiliximab, and 43% were given the humanized antibody daclizumab, which was given for a mean of 2.6 doses and an average total duration of 26 days per patient. No patient received daclizumab for longer than 5.6 months. Two patients received both an anti-CD 25 monoclonal antibody and a short course of anti-thymocyte globulin. One patient received one perioperative dose of daclizumab but was converted to a 3-day course of anti-thymocyte globulin because of temporary delayed graft function and a clinical decision to delay the initiation of oral tacrolimus. The other patient was begun on anti-thymocyte globulin but received one dose of basiliximab because of a clinical concern about a failure to adequately deplete CD3 + T cells. During the 1 year of follow-up, 99% of patients received tacrolimus, 98% received mycophenolate mofetil, 59% received prednisone, 19% received sirolimus, 7% received azathioprine, 2% received Cyclosporine, and 1% received leflunomide (Table 1) .
Clinical outcomes: All transplants were technically successful. No patient had delayed graft function, defined as the need for dialysis in the first week. The mean eGFR at 1, 6, and 12 months was 72 AE 26, 74 AE 21 and 74 AE 25 mL/min/1.73 m 2 , respectively. There were no deaths; two graft losses occurred, yielding an actual 1-year graft survival of 98%.
BPAR data
In the 99 patients with evaluable BPAR data, 24 (24%) patients developed a total of 30 BPAR episodes. Acute cellular rejection (ACR) as a single entity represented 93% of all rejection episodes. While all 24 patients with rejection had ACR, two of these patients also developed concurrent antibody-medicated rejection (AMR). Fourteen (58%) of the 24 patients had biopsy changes classified as "borderline." No patient developed isolated or chronic AMR. There were no significant differences in demographic data, physical parameters, HLA matching, or type of immunosuppressive medications between those with and those without BPAR. Specifically, there were no significant associations between the diagnosis of BPAR and the use of either tacrolimus, mycophenolate mofetil, or sirolimus. There was a nonsignificant association between the use of corticosteroids as maintenance immunosuppression and the diagnosis of BPAR. (p = 0.077) ( Table 2. ) Similarly, there were no associations between the specific induction antibodies used and the diagnosis of BPAR. There was a nonsignificant trend toward increased BPAR in patients who manifested any baseline sensitization Table 2 ). Using multivariable logistic regression, there was no association with BPAR and either pretransplantation CMV/EBV serostatus or posttransplantation development of viral infection or viremia. We also found no association with any of these parameters when patients with borderline changes were removed from the analyses (data not shown).
Alloantibodies
At transplantation, 21 (20%) of 106 patients had preformed HLA-specific antibodies, although only four had donor HLA-specific antibodies (DSAs). None had There was a strong correlation between the generation of HLA-specific dnDSAs and the number of HLA mismatches present (p = 0.002). There were no associations between dnDSAs and any demographic features, posttransplantation physical parameters, or type of immunosuppressive medications (induction, maintenance or steroid vs. steroid-free). There was a borderline association between donor CMV seropositivity and the development of dnDSA (p = 0.058). However, we found no association between either recipient CMV serostatus or the development of CMV viremia/viral infection and the generation of dnDSAs.
Alloimmune failure
Of 102 patients in whom all data were available, 40 (39%) patients experienced AF (BPAR or dnDSAs). Twenty-three patients developed dnDSAs and 24 patients developed BPAR, with seven patients having both.
A significantly lower proportion of Hispanic/Latino patients had AF (p = 0.021) ( Table 2 ). There were no other associations between the demographic characteristics or a specific immunosuppressive regimen and AF. There was a significant association observed between HLA matching and AF (p = 0.018), but this was due to the significant association between HLA matching and dnDSAs (see earlier) (p = 0.002); there was no demonstrable relationship between HLA matching and BPAR (p = 0.219) ( Table 2) . Importantly, there were no associations of AF with either viremia or clinical viral infection (Table 2 ). When we examined the temporality of viral infection/viremia, we found that preceding clinical viral infection or viremia was not associated with subsequent AF, BPAR, or DSAs. Similarly, we observed no associations between AF or eGFR and the pretransplantation CMV or EBV serostatus.
Pretransplantation serology and outcomes
At enrollment, patients were classified as either seropositive for both CMV and EBV ( +/+ ; n = 40; 38%), seronegative for both ( À/À ; n = 28; 26%), or "split serology" (CMV + EBV À or CMV À EBV + ; n = 38; 36%) ( Table 3) . As expected, patients negative for both serologies were significantly younger than those in the other groups (p ≤ 0.001). Patients who were seropositive for both CMV and EBV were the least likely to have pretransplantation sensitization (i.e. PRA >0%; p = 0.022) ( Table 3 ).
There were no associations between pretransplantation serostatus and BPAR or dnDSAs (see earlier). In addition, posttransplantation viremia rates were similar based on pretransplantation serostatus. The eGFR levels were not significantly different between serology groups at 6 and 12 months.
Posttransplantation viremia
Of a total of 106 patients, 77 (73%) developed viremia, as defined by either the central or local laboratory assessments. The most common viruses were EBV (n = 36, 34%), CMV (n = 24, 23%), BKV (n = 24, 23%), and JC virus (n = 22, 21%) ( Table 3 ). Seven of the 22 patients with JC viremia showed PCR results of >1000 copies/mL and two had levels exceeding 100 000 copies/mL. Other viruses were detected sporadically (Table 3 ). There were 30 instances of patients having two or more viremias, not all concurrent.
As expected, there was a significant association between the presence of viremia as documented by PCR and the development of viral infection (p = 0.007) ( Table 3) . Nevertheless, only one-third of patients who had viremia by PCR actually demonstrated clinical signs of viral infection. By univariate analysis, we observed no relationships between the development of viremia with either the type of induction therapy used, anti-thymocyte globulin use, prior antirejection therapy, or any specific immunosuppression regimen including corticosteroid use. There were no associations between viremia and age, race, ethnicity or other patient characteristics. There were no differences in mean eGFR values when comparing patients with or without viremia (Table 3) .
Patients who developed viremia did not differ from nonviremic patients with regard to height, weight, or BMI Z scores at transplantation. However, at 1 year posttransplantation, viremic patients weighed significantly less (p = 0.035) and had a significantly lower BMI (p = 0.040). The mean and median BMI Z scores in viremic patients at 12 months were 0.5 and 1, respectively, while in nonviremic patients, the mean and median values were 1.1 and 2 (Figure 2 ), suggesting either increased viral susceptibility in those with more slowly increasing BMI or a significant metabolic demand associated with viremia and/or control thereof.
Clinical viral infection
Among the 106 patients studied, there were 54 instances of locally diagnosed clinical infection (Table 1 ). Viral infections were most numerous (n = 27), followed by bacterial infections (n = 22). When clinical infection was diagnosed, each center adjusted maintenance immunosuppression in accord with center-specific practice. As a group, first infections posttransplantation were most frequently viral When we added the transplant center to the covariates, these conclusions did not change. Other factors not related to clinical viral infection included age, pretransplantation CMV/EBV seropositivity, BPAR, dnDSAs, and HLA mismatch (≥2 vs. <2).
"Pure group" analysis A number of the patients exhibited both rejection and viremia at different times, confounding the analyses of these distinct conditions. Thus, we defined three "phenotypically pure" groups to more precisely explore differences between these conditions of interest (Figures 1  and 3 ). Patients were characterized as those who experienced rejection-only (n = 15), viremia only (n = 15), or neither rejection nor viremia (n = 17). For some analyses, we further divided the viremia-only group into those with clinical viral infection (n = 8) and those with only highlevel viremia (>10 000 copies) (n = 7). We then analyzed the mean height, weight, and BMI in each of the groups.
The no-rejection/no-viremia group had the highest weight and BMI Z scores at baseline and month 12. Patients with viremia showed a mean weight Z score at baseline of À1.3, which was numerically lower (p = 0.086) than that in the other two pure groups; this borderline association continued to 12 months when the mean weight Z score was À0.3. (p = 0.052). Mean BMI Z scores were also numerically lower in the viremia group at baseline, although the difference reached borderline significance only at 12 months (p = 0.080) (Figure 3 ). However, on further analysis, when we separated patients into those with clinical viral infection versus high-level viremia only, we noted that those with isolated high-level viremia showed no associations with low weight and BMI Z scores at any time point. On the other hand, patients who developed clinical viral infection had at baseline significantly lower Z scores for weight (À2.1) (p = 0.028) and BMI (À1.2) (p = 0.048), and the weight difference persisted to 12 months (p = 0.038) (Figure 3 ). Thus, with precise stratification, low weight and BMI were preceding risk factors for subsequent clinical viral infection.
Flow cytometric analyses: There were no significant differences in any memory T cell compartment at baseline that predicted BPAR or dnDSAs (data not shown). At month 12, both the percentage and absolute numbers of CD4 + T cells were significantly decreased in rejecters compared with nonrejecters (p = 0.007 and 0.011, respectively) (Figure 4) . Similarly, there were significantly reduced percentages (Figure 4 ) and absolute numbers of na€ ıve CD4 + T cells in rejecters compared with nonrejecters at month 12 (p = 0.033 and 0.0004, respectively) (absolute numbers not shown). The percentage of CD8 + T cells was significantly increased at 12 months in patients who experienced rejection (p = 0.006).
As with BPAR, memory subsets at baseline were not related to the subsequent development of dnDSAs. In Height Z scores patients with dnDSAs, there was a decrease in the percentage of CD4 + na€ ıve cells from day 1 to month 12 (p = 0.012), consistent with the requirement for T cell help for alloantibody formation. There were no differences in memory subsets before transplantation that signaled a risk for viremia and/or viral infection. Additionally, there were no memory subset patterns that related to viral disease over the first year, either in the entire study group or in the three "phenotypically pure" groups.
Discussion
The IMPACT study is the first to prospectively examine the relationships between viremia/viral infection, alloimmune events, BMI/weight, and T cell immunophenotyping in pediatric kidney transplant recipients. Our data indicate that viremia is very common, occurring in 73% of children regardless of immunosuppression or viral serostatus. We found no relationships between CMV and/or EBV serostatus or memory T cell phenotypes at the time of transplantation and subsequent transplantation outcome through 1 year of follow-up. An unexpected and potentially important observation is that clinical viral infection was significantly associated with baseline low BMI and weight. Moreover, both viremia and viral infection appeared to be associated with less weight gain, lower BMI gains over the first year, and lower BMI at 12 months after transplantation.
We found viremia in almost three-quarters of our patients. The incidences of EBV, CMV, and BKV were consistent with those in other reported pediatric series, as well as in one adult series (20) (21) (22) (23) . Previous large studies and surveys of posttransplantation viral infection in pediatric kidney transplantation have examined only EBV, CMV, and BKV. Ours is the first pediatric kidney transplant multicenter study that has looked for evidence not only of those three viruses but also for HHV6, HHV7, HHV8, adenovirus, and JC virus. A surprising finding was the high prevalence of JC viremia, found in 21% of our patients. Previously, posttransplantation JC viremia was generally assumed to be transient and infrequent (24) (25) (26) . Primary JC virus infection is most common in childhood, adolescence, and young adulthood. Approximately 50% of normal children are seropositive by ages 9-11 years, and this number rises to 69% of all organ transplant recipients by age 29 (27) . The finding of JC viremia in our immunosuppressed population warrants more investigation, because this virus has been associated with such long-term morbidities as progressive multifocal leukoencephalopathy (27) , JC polyomavirus encephalopathy (28, 29) , JC nephropathy (29) , and central nervous system tumors (30).
Our study uncovered a new and potentially important interaction between children's underweight status and clinical outcome. In our cohort, clinical viral infection was significantly more likely to occur in patients with low baseline weight and BMI Z scores. Malnutrition in children is associated with immune defects (31) . It is, therefore, understandable that underweight pediatric transplant recipients may experience more viral infections and may have other morbidities as well. Ku et al recently reported that pediatric transplant recipients classified as "underweight" have higher mortality rates than those with weight/BMI in the normal range (32). Protein energy wasting in children in the United States with chronic renal insufficiency ranges from 7% to 20% (33) . Recent examinations of two large databases found that 6% and 10% of patients beginning renal replacement therapy were underweight in Europe and the United States, respectively (32, 34) . Children on maintenance dialysis for <1 year were more likely to be underweight than were those who spent 1-3 years on dialysis (34) . Thus, a small but important proportion of children with chronic kidney disease and ESRD appear to be undernourished, and this may have important clinical implications. Our results and those of Ku et al suggest that the effects of underweight status in pediatric transplant recipients deserve careful study.
The IMPACT study sought to establish whether viral infection and/or viremia could influence alloimmune events and allograft outcome in the first posttransplantation year. While some clinical studies have linked viral infection with allograft dysfunction and rejection (17, (35) (36) (37) , we observed no increase in BPAR with either viremia or clinical viral infection, including CMV and BKV. The lack of association between CMV viremia and rejection could be due in part to our use of valganciclovir prophylaxis in almost every patient (10, 17) . We also found no association between any viremia and the generation of dnDSAs. Prior exposure to the latent herpesviruses CMV and EBV, as denoted by pretransplantation seropositivity, also did not appear to influence the subsequent incidence of rejection or DSA formation. We did find a borderline association between donor CMV seropositivity and posttransplantation DSAs, but the relevance of this observation is unclear, given the absence of any association between DSAs and recipient CMV serostatus or viremia. Taken together, our findings in this prospective study strongly suggest that viral infections do not directly lead to BPAR in children in the first posttransplantation year. However, other studies suggest that viral infection may adversely affect long-term allograft outcome (38) (39) (40) . For this reason, longer-term follow-up of our patients and similar pediatric cohorts is warranted.
There are few data in pediatric kidney transplantation examining the clinical value of T cell immunophenotyping. Reports have been equivocal as to the importance of memory subset analysis as a prognostic tool (41) . Our study prospectively assessed associations between bulk T cell memory and transplant outcomes. While bulk T cell phenotype at baseline did not anticipate rejection, rejection and/or its clinical treatment was associated with subsequent expansion of cytotoxic CD8 + T cell effectors and a reduction in antigen inexperienced CD4 + T cells. More in-depth analyses to include regulatory, exhausted, and senescent phenotypes are currently in progress.
Our study can reasonably be applied to today's pediatric kidney transplant population. The immunosuppressive regimens were consistent with those used in the majority of pediatric transplant centers (42) . The graft and patient survival rates were in keeping with expected modern results (2, 3, 43) . The eGFR results in our patients were somewhat lower than those reported in the NAPRTCS database (https://web.emmes.com/study/ped/ annlrept/annualrept2014.pdf). However, we used the updated Schwartz formula, which gives results that are somewhat lower than the older Schwartz formula that the NAPRTCS Registry used (18) . The incidence of BPAR was similar to that in previous reports (42) . Similarly, both the prevalence of dnDSAs and the prominence of class II DSAs in our patients are similar to other reported series (4, (44) (45) (46) . Similar to the findings of Kim et al (45), we did not find an association between BPAR and DSAs. This is not surprising because previous pediatric studies, which did not include protocol biopsies, have found that it can take 1 year or longer for patients who generate dnDSAs to manifest biopsy changes of AMR (44) . Most pediatric studies agree that dnDSAs, and particularly class II DSAs, are associated with deteriorating renal function (4, 45) .
Our study has some important limitations. The sample size of 106 transplanted patients and the follow-up of only 1 year limit our ability to draw conclusions about such clinical questions as the relationship between dnDSA generation and late BPAR and the long-term effects of viremia/viral infection on outcome. Moreover, the relatively small number of patients who were viremia free limits our ability to categorically define the clinical correlates of freedom from viremia. Induction and maintenance immunosuppressive regimens were not harmonized between centers or patients, and the study was not powered to evaluate the effects of different immunosuppressive regimens. Finally, the racial/ethnic composition of our cohort limits the generalizability of our findings to the general pediatric kidney transplant population.
In summary, our study uncovers some important clinical interactions and associations between viremia, viral infection, indices of nutrition, and T cell phenotyping. Further studies using the IMPACT database are in progress to examine and expand in greater detail the findings described in this report. These findings can serve to generate specific medical practices that will improve the outcome of pediatric kidney transplantation.
